Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2018

View Archived Issues

Disconnecting bone building from resorption may be osteoporosis strategy

Myocardial regeneration outcomes using WJMSCs presented from pilot cohort of CIRCULATE-AMI study

Identification of a mosquito salivary gland protein that partially limits malaria transmission

MPO-0112 ameliorates scopolamine-induced cognitive impairment in mice

Ozalin becomes the first oral pediatric sedative to receive marketing authorization in Europe

BioArctic enters research collaboration with Brain Biomarker Solutions in Alzheimer's

New sphingolipid-biased phenotypic approach for the discovery of new targets and new leads

XBiotech presents positive interim data for initial cohort of bermekimab pilot study

FDA approves subcutaneous Actemra for active systemic juvenile idiopathic arthritis

Bone Therapeutics reports final data from phase I/IIa study of ALLOB in delayed-union fractures

Merck & Co. evaluating MK-1654 in phase I/II study in healthy preterm and full-term infants

FDA approves Lumoxiti for relapsed or refractory hairy cell leukemia

Patient recruitment ongoing in phase I study of INCAGN-02390

TD-1473 being evaluated in phase II study in patients with active Crohn's disease

Natera enters agreement with Bristol-Myers Squibb for use of Signatera ctDNA assay in Opdivo trial

Biogen begins clinical evaluation of BIIB-078 in C9ORF72-associated ALS

Arrowhead Pharmaceuticals patents RNAi for thromboembolic disorders

GSK begins first-in-human study of GSK-3439171A

Hanyang University presents new MAPK 10 inhibitors

Merck & Co. synthesizes new IDO1 inhibitors

Monash University and GSK present discovery of novel compound for treatment of Chagas disease

NTZ-2020 and NTZ-2027 as promising new candidates for the treatment and diagnosis of CNS disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.